IP Library › Granted Patent US 12,662,523
Granted Patent B2
US 12,662,523 · App. 17/608,546 · Granted Jun 23, 2026

Pharmaceutical formulations containing CD80 extracellular domain-Fc fusion proteins

Inventor: Yong Quan (Dublin, CA)
Assignee: FIVE PRIME THERAPEUTICS, INC.
C07K14/70532A01K67/0271A61K9/0019A61K47/26A61P35/00A01K2227/105A01K2267/0331A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,662,523
App. No.
17/608,546
Granted
Jun 23, 2026
Kind
B2
Abstract

The present disclosure provides pharmaceutical compositions comprising CD80 extracellular domain (ECD)-fragment crystallizable (Fc) fusion molecules. The present disclosure also provides methods for treating solid tumors by administering such pharmaceutical compositions.

Claims (16)

1 . A pharmaceutical composition consisting of (i) sialylated CD80 ECD-Fc fusion molecules, (ii) about 20 mM L-histidine, (iii) about 270 mM sucrose, and (iv) about 0.05% weight/volume polysorbate 20, wherein the pH of the composition is about 6.7.

2 . A pharmaceutical composition consisting of (i) sialylated CD80 ECD-Fc fusion molecules, (ii) about 20 mM L-histidine, (iii) about 270 mM sorbitol, and (iv) about 0.05% weight/volume polysorbate 20, wherein the pH of the composition is about 6.7.

3 . A syringe or vial comprising the pharmaceutical composition of claim 1 .

4 . The pharmaceutical composition of claim 1 , wherein the concentration of CD80 ECD-Fc fusion molecules is about 5 mg/ml to about 15 mg/ml.

5 . The pharmaceutical composition of claim 4 , wherein the concentration of the CD80 ECD-Fc fusion molecules is about 10 mg/ml.

6 . The pharmaceutical composition of claim 1 , wherein the composition is a liquid.

7 . The pharmaceutical composition of claim 1 , wherein the composition is for intravenous administration.

8 . The pharmaceutical composition of claim 1 , wherein the CD80 ECD-Fc fusion molecules comprise a human CD80 ECD and a human IgG1 Fc domain.

9 . The pharmaceutical composition of claim 1 , wherein the CD80 ECD-Fc fusion molecules comprise 15-60 moles sialic acid (SA) per mole of fusion protein.

10 . The pharmaceutical composition of claim 2 , wherein the concentration of CD80 ECD-Fc fusion molecules is about 5 mg/ml to about 15 mg/ml.

11 . The pharmaceutical composition of claim 10 , wherein the concentration of the CD80 ECD-Fc fusion molecules is about 10 mg/ml.

12 . The pharmaceutical composition of claim 2 , wherein the composition is a liquid.

13 . The pharmaceutical composition of claim 2 , wherein the composition is for intravenous administration.

14 . The pharmaceutical composition of claim 2 , wherein the CD80 ECD-Fc fusion molecules comprise a human CD80 ECD and a human IgG1 Fc domain.

15 . The pharmaceutical composition of claim 2 , wherein the CD80 ECD-Fc fusion molecules comprise 15-60 moles sialic acid (SA) per mole of fusion protein.

16 . A syringe or vial comprising the pharmaceutical composition of claim 2 .